Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

Literature DB >> 24217961

Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

J Ervens¹, M Ghannoum, B Graf, S Schwartz.

Abstract

A 45-year-old male with rhinocerebral mucormycosis (Rhizopus oryzae), refractory to liposomal amphotericin B and posaconazole, received isavuconazole salvage therapy. Initial isavuconazole plasma and tissue levels were 0.76-0.86 μg/mL and 1.09-1.38 μg/g. Plasma levels increased to 1.3-3.24 μg/mL with reduced comedication. Isavuconazole was well tolerated, and the patient has remained disease-free 24 months post-antifungal therapy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 24217961 DOI： 10.1007/s15010-013-0552-6

Source DB: PubMed Journal: Infection ISSN： 0300-8126 Impact factor: 3.553

13 in total

Review 1. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors: M A Ghannoum; L B Rice
Journal: Clin Microbiol Rev Date: 1999-10 Impact factor: 26.132

2. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.

Authors: P E Verweij; G M González; N P Wiedrhold; C Lass-Flörl; P Warn; M Heep; M A Ghannoum; J Guinea
Journal: J Chemother Date: 2009-06 Impact factor: 1.714

3. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).

Authors: F Lanternier; E Dannaoui; G Morizot; C Elie; D Garcia-Hermoso; M Huerre; D Bitar; F Dromer; O Lortholary
Journal: Clin Infect Dis Date: 2012-02 Impact factor: 9.079

4. Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis.

Authors: Thomas J Walsh; Bruce E Bloom; Dimitrios P Kontoyiannis
Journal: Clin Infect Dis Date: 2012-02 Impact factor: 9.079

5. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.

Authors: A Skiada; L Pagano; A Groll; S Zimmerli; B Dupont; K Lagrou; C Lass-Florl; E Bouza; N Klimko; P Gaustad; M Richardson; P Hamal; M Akova; J F Meis; J-L Rodriguez-Tudela; E Roilides; A Mitrousia-Ziouva; G Petrikkos
Journal: Clin Microbiol Infect Date: 2011-07-01 Impact factor: 8.067

6. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation.

Authors: Eric Dannaoui; Patrick Schwarz; Michal Slany; Juergen Loeffler; Anne Tomine Jorde; Manuel Cuenca-Estrella; Philippe M Hauser; Raghdaa Shrief; Michel Huerre; Tomas Freiberger; Peter Gaustad; Juan-Luis Rodriguez-Tudela; Jacques Bille; David W Denning; Stéphane Bretagne; Olivier Lortholary
Journal: J Clin Microbiol Date: 2010-04-07 Impact factor: 5.948

Review 7. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors: Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941

8. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

Authors: Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal: Clin Infect Dis Date: 2008-08-15 Impact factor: 9.079

Review 9. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.

Authors: Vijayalakshmi Nagappan; Stan Deresinski
Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079

10. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors: Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal: Antimicrob Agents Chemother Date: 2006-01 Impact factor: 5.938

22 in total

1. Isavuconazole treatment of a patient with disseminated mucormycosis.

Authors: Driele Peixoto; Lisa S Gagne; Sarah P Hammond; Erin T Gilmore; Amy C Joyce; Robert J Soiffer; Francisco M Marty
Journal: J Clin Microbiol Date: 2014-01-08 Impact factor: 5.948

Review 2. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors: Romuald Bellmann; Piotr Smuszkiewicz
Journal: Infection Date: 2017-07-12 Impact factor: 3.553

3. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.

Authors: Anuradha Chowdhary; Pradeep Kumar Singh; Shallu Kathuria; Ferry Hagen; Jacques F Meis
Journal: Antimicrob Agents Chemother Date: 2015-10-05 Impact factor: 5.191

10. Case Report: Rhizopus arrhizus Rhino-Orbital-Cerebral Mycosis and Lethal Midline Granuloma: Another Fungal Etiological Agent.

Authors: Dong Ming Li; Li De Lun; Jie Ge; Gong Jie Zhang; Xin Lun Li; G Sybren de Hoog
Journal: Front Med (Lausanne) Date: 2021-06-02